Chu Y - Search Results

1

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.

Timmers M, Roex G, Wang Y, Campillo-Davo D, Van Tendeloo VFI, Chu Y, Berneman ZN, Luo F, Van Acker HH, Anguille S. Timmers M, et al. Among authors: chu y. Front Immunol. 2019 Jul 16;10:1613. doi: 10.3389/fimmu.2019.01613. eCollection 2019. Front Immunol. 2019. PMID: 31379824 Free PMC article. Review.

2

TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells.

Zhang Y, Luo F, Cai Y, Liu N, Wang L, Xu D, Chu Y. Zhang Y, et al. Among authors: chu y. J Immunol. 2011 Feb 15;186(4):1963-9. doi: 10.4049/jimmunol.1002320. Epub 2011 Jan 7. J Immunol. 2011. PMID: 21217015

3

Low-dose curcumin leads to the inhibition of tumor growth via enhancing CTL-mediated antitumor immunity.

Luo F, Song X, Zhang Y, Chu Y. Luo F, et al. Among authors: chu y. Int Immunopharmacol. 2011 Sep;11(9):1234-40. doi: 10.1016/j.intimp.2011.04.002. Epub 2011 Apr 15. Int Immunopharmacol. 2011. PMID: 21497674

4

Trichosanthin enhances anti-tumor immune response in a murine Lewis lung cancer model by boosting the interaction between TSLC1 and CRTAM.

Cai Y, Xiong S, Zheng Y, Luo F, Jiang P, Chu Y. Cai Y, et al. Among authors: chu y. Cell Mol Immunol. 2011 Jul;8(4):359-67. doi: 10.1038/cmi.2011.12. Epub 2011 May 16. Cell Mol Immunol. 2011. PMID: 21572449 Free PMC article.

5

Mouse glioma immunotherapy mediated by A2B5+ GL261 cell lysate-pulsed dendritic cells.

Xu M, Yao Y, Hua W, Wu Z, Zhong P, Mao Y, Zhou L, Luo F, Chu Y. Xu M, et al. Among authors: chu y. J Neurooncol. 2014 Feb;116(3):497-504. doi: 10.1007/s11060-013-1334-9. Epub 2014 Jan 8. J Neurooncol. 2014. PMID: 24398615

6

Pseudomonas aeruginosa mannose-sensitive hemagglutinin promotes T-cell response via toll-like receptor 4-mediated dendritic cells to slow tumor progression in mice.

Zhang M, Luo F, Zhang Y, Wang L, Lin W, Yang M, Hu D, Wu X, Chu Y. Zhang M, et al. Among authors: chu y. J Pharmacol Exp Ther. 2014 May;349(2):279-87. doi: 10.1124/jpet.113.212316. Epub 2014 Mar 12. J Pharmacol Exp Ther. 2014. PMID: 24623801

7

Systemic injection of TLR1/2 agonist improves adoptive antigen-specific T cell therapy in glioma-bearing mice.

Zhang Y, Luo F, Li A, Qian J, Yao Z, Feng X, Chu Y. Zhang Y, et al. Among authors: chu y. Clin Immunol. 2014 Sep;154(1):26-36. doi: 10.1016/j.clim.2014.06.004. Epub 2014 Jun 11. Clin Immunol. 2014. PMID: 24928324

8

Low percentage of CD24hiCD27⁺CD19⁺ B cells decelerates gastric cancer progression in XELOX-treated patients.

Yang J, Li W, Luo F, Zhao N, Zhang W, Zhang D, Qian J, Yu Y, Zheng X, Wang Y, Feng Y, Liu T, Chu Y. Yang J, et al. Among authors: chu y. Int Immunopharmacol. 2015 Jun;26(2):322-7. doi: 10.1016/j.intimp.2015.04.011. Epub 2015 Apr 18. Int Immunopharmacol. 2015. PMID: 25899086

9

Biological Response Modifier in Cancer Immunotherapy.

Liu R, Luo F, Liu X, Wang L, Yang J, Deng Y, Huang E, Qian J, Lu Z, Jiang X, Zhang D, Chu Y. Liu R, et al. Among authors: chu y. Adv Exp Med Biol. 2016;909:69-138. doi: 10.1007/978-94-017-7555-7_2. Adv Exp Med Biol. 2016. PMID: 27240457 Review.

10

Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2(+) gastric cancer.

Luo F, Qian J, Yang J, Deng Y, Zheng X, Liu J, Chu Y. Luo F, et al. Among authors: chu y. Cell Res. 2016 Jul;26(7):850-3. doi: 10.1038/cr.2016.81. Epub 2016 Jun 24. Cell Res. 2016. PMID: 27339087 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,201 results

Search Page

Filters